Heterogeneity of cognitive decline in dementia: taking into account variable time-zero severity
The Problem
Understanding the progression of Alzheimer’s disease (AD) is critical to the optimal design of clinical trials, and the ability to plan an individuals care. However, the current FDA-approved model of AD progression only takes into account age, gender and the main genetic risk factor (APOE). While this needs to be improved, this work is held back by data with short follow-up and many data analysis challenges. A vast amount of data on AD progression is available through anonymised medical records, but a key problem is that patients can be at different disease stages at first assessment.
Our Research
In this project we aim to overcome this problem through the introduction of a novel approach – Temporal Clustering – that jointly learns a set of common trajectories and a new time frame in which, at first assessments individuals are predicted to have been at a similar disease stage.
Theme
Precision Medicine
Disease
Mental Health
People
Elizabeth Baker
Chris Wallace
Alice Parodi
Richard Dobson
Publications: http://biorxiv.org/content/early/2016/06/27/060830
Impact in research
- Blood pressure and incidence of twelve cardiovascular diseases
- Blood tests for the early identification of Alzheimer's Disease
- Breaking records: Using health records to explore antibiotic prescribing practice
- CALIBER cardiovascular disease prevention projects
- Cognitive workload of health technologies
- Heterogeneity of cognitive decline in dementia: taking into account variable time-zero severity
- Infection Response through Virus genomics (ICONIC)
- International comparisons of 'big' health record data: application to cardiovascular diseases
- Investigating adverse effects of psychiatric drugs through data-mining of electronic health records
- KConnect
- Laboratory-confirmed respiratory infections as vascular triggers
- Large scale omics data integration for biomarker discovery, drug repositioning and screening for new therapeutic targets for Alzheimer's disease
- Lipids and cardiovascular diseases in CALIBER
- 'Nothing about us, without us.' Involvement of Experts by Experience in Homeless and Inclusion Health Research
- Prognosis Research Partnership
- Reactivation of varicella zoster virus and vascular outcomes
- Real-time detection of influenza outbreaks in hospitals: demonstrating infection response through virus genomics (ICONIC)
- The prescription-persistence cascade in cardiovascular disease-an opportunity for big data research
- Tuberculosis in migrants
- Video Observed Therapy for TB – The world’s first randomised controlled trial of smartphone enabled “Video Observed Therapy” to support patients to complete tuberculosis treatment